<DOC>
	<DOCNO>NCT00005840</DOCNO>
	<brief_summary>This phase I trial study side effect best dose combination chemotherapy give radiation therapy treat patient stage III stage IV endometrial cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Stage III Stage IV Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety maximum tolerated dos paclitaxel cisplatin administer radiotherapy patient stage III IV endometrial cancer . II . Assess time disease progression overall survival patient treat regimen . OUTLINE : This dose-escalation study paclitaxel cisplatin . Patients receive paclitaxel IV 1 hour cisplatin IV day 1 , 8 , 15 , 22 , 29 , 36 . Patients also undergo whole abdominal radiotherapy 5 consecutive day weekly 6 week . Cohorts 3-6 patient receive escalate dos paclitaxel cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat dose level . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 3-48 patient accrued part I 14-20 patient accrue part II study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm surgical stage III IV endometrial cancer Any stage clear serous papillary endometrial cancer Positive paraaortic lymph node allow Tumor must surgically reduce 2 cm less within 8 week study Must hysterectomy bilateral salpingooophorectomy No recurrent disease No metastases lung liver parenchyma inguinal scalene lymph node Performance status GOG 02 Absolute neutrophil count great 2,000/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Creatinine great 1.5 time ULN No prior concurrent malignancy past 5 year except nonmelanoma skin cancer No prior chemotherapy No prior radiotherapy See Disease Characteristics No 8 week since prior surgery No prior anticancer therapy would preclude study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>